Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00536991 | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer | terminated | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00084864 | Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate | terminated | Phase 2 | 25 | Roswell Park Cancer InstituteOTHER | 1 | Jun 12, 2017 |
| clinicaltrials |
| NCT01558492 | Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer | terminated | Phase 2 | 3 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT01338012 | Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer(mCRPC) | terminated | Phase 2 | 8 | DendreonINDUSTRY | 1 | Jun 5, 2017 | clinicaltrials |
| NCT01385293 | BKM120 in Metastatic Castration-resistant Prostate Cancer | terminated | Phase 2 | 30 | Andrew J. Armstrong, MDOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT01215032 | Metformin in Castration-Resistant Prostate Cancer | terminated | Phase 2 | 21 | Massachusetts General HospitalOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT01735396 | Abiraterone Acetate Trial in African American Prostate Cancer Patients | terminated | Phase 2 | 11 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT01828476 | Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer | terminated | Phase 2 | 13 | Rutgers, The State University of New JerseyOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT00459810 | Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer | terminated | Phase 2 | 21 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00482274 | Docetaxel in Treating Patients With Relapsed Prostate Cancer | terminated | Phase 2 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02840162 | Pre-Prostatectomy Celecoxib or Placebo | terminated | Phase 2 | 34 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01450683 | Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy | terminated | Phase 2 | 4 | Stanford UniversityOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT02656615 | Abiraterone-Rechallenge Study for CRPC Patients(ABI-RE) | terminated | Phase 2 | 4 | Aurelius OmlinOTHER | 1 | Mar 24, 2017 | clinicaltrials |
| NCT02483884 | PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer | terminated | Phase 1 / Phase 2 | 30 | Lantheus Biosciences Ltd.INDUSTRY | 2 | Mar 22, 2017 | clinicaltrials |
| NCT01817738 | Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 197 | CureVacINDUSTRY | 8 | Feb 17, 2017 | clinicaltrials |
| NCT00879619 | Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | John P. FruehaufOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT01913197 | Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy | terminated | Phase 1 / Phase 2 | 2 | St. Luke's-Roosevelt Hospital CenterOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT00686036 | Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy(ZENITH) | terminated | Phase 2 | 17 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 21, 2016 | clinicaltrials |
| NCT00861471 | Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 24 | NYU Langone HealthOTHER | 1 | Jun 30, 2016 | clinicaltrials |
| NCT02140138 | An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer | terminated | Phase 2 | 35 | CureVacINDUSTRY | 1 | Jun 13, 2016 | clinicaltrials |
| NCT00503984 | A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 22 | University of MiamiOTHER | 1 | Jun 9, 2016 | clinicaltrials |
| NCT00985738 | Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer | terminated | Phase 2 | 16 | University of Colorado, DenverOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT01981707 | F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer(PRECHOL) | terminated | Phase 2 / Phase 3 | 12 | University Hospital, GrenobleOTHER | 1 | Apr 28, 2016 | clinicaltrials |
| NCT00447473 | Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer | terminated | Phase 2 | 31 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00448097 | Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy | terminated | Phase 2 | 7 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00450008 | Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer | terminated | Phase 2 | 9 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00521274 | Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer | terminated | Phase 2 | 11 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00521781 | Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer | terminated | Phase 2 | 14 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01603420 | External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer | terminated | Phase 2 / Phase 3 | 2 | Proton Collaborative GroupNETWORK | 1 | Mar 14, 2016 | clinicaltrials |
| NCT00734851 | Multimodality Phase II Study in Prostate Cancer | terminated | Phase 2 | 36 | Duke UniversityOTHER | 1 | Dec 23, 2015 | clinicaltrials |
| NCT00932672 | Atkins Diet and Prostate Cancer Clinical Trial | terminated | Phase 2 | 45 | Duke UniversityOTHER | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00381836 | Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer | terminated | Phase 2 / Phase 3 | 140 | University of AarhusOTHER | 1 | Dec 4, 2015 | clinicaltrials |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 79 | Otsuka Novel Products GmbHINDUSTRY | 1 | Oct 20, 2015 | clinicaltrials |
| NCT00585416 | Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer | terminated | Phase 2 | 23 | University of Wisconsin, MadisonOTHER | 1 | Oct 2, 2015 | clinicaltrials |
| NCT02480010 | A Study of Pertuzumab in Participants With Prostate Cancer | terminated | Phase 2 | 68 | Hoffmann-La RocheINDUSTRY | 6 | Sep 18, 2015 | clinicaltrials |
| NCT01705652 | Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients(Nexrutine) | terminated | Phase 2 | 21 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT00118066 | Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia | terminated | Phase 2 | 12 | Rutgers, The State University of New JerseyOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT00176293 | Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer | terminated | Phase 2 | 2 | University of KentuckyOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00217464 | Fulvestrant in Treating Patients With Recurrent Prostate Cancer | terminated | Phase 2 | 17 | Roswell Park Cancer InstituteOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT01267266 | Saracatinib in Treating Patients With Prostate Cancer | terminated | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Apr 1, 2015 | clinicaltrials |
| NCT00058214 | Perifosine in Treating Patients With Recurrent Prostate Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | terminated | Phase 1 / Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 5, 2015 | clinicaltrials |
| NCT01469338 | Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel | terminated | Phase 2 | 9 | University of Southern CaliforniaOTHER | 1 | Nov 24, 2014 | clinicaltrials |
| NCT01531205 | Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT00753220 | Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer(CRITICAL) | terminated | Phase 1 / Phase 2 | 7 | Bostwick LaboratoriesINDUSTRY | 1 | Nov 4, 2014 | clinicaltrials |
| NCT00918385 | Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer(ARS) | terminated | Phase 2 | 57 | Duke UniversityOTHER | 1 | Oct 29, 2014 | clinicaltrials |
| NCT01020305 | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | Sandy SrinivasOTHER | 1 | Oct 13, 2014 | clinicaltrials |
| NCT01704027 | Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer | terminated | Phase 2 | 28 | Centre Georges Francois LeclercOTHER | 1 | Sep 18, 2014 | clinicaltrials |
| NCT00385827 | A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) | terminated | Phase 2 | 106 | Centocor, Inc.INDUSTRY | 7 | Aug 20, 2014 | clinicaltrials |
| NCT00004050 | Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer | terminated | Phase 2 | 13 | VicalINDUSTRY | 1 | Jul 29, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jun 14, 2017source: clinicaltrials